Ethics and governance for digital disease surveillance

Mello, Michelle M.; Wang, C. Jason

doi:10.1126/science.abb9045

Cited by 114 publications

(99 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the enhanced availability of health-related data (especially patient data), concerns have been raised regarding data security and privacy. 75 For example, demographics and DNA sequencing data have an increased risk of making patients identifiable. Efforts should be made to scrutinise each stage in the data life cycle.…”

Section: Challenges In Data Sharing and Securitymentioning

confidence: 99%

Artificial intelligence in COVID-19 drug repurposing

Zhou

Wang

Tang

et al. 2020

The Lancet Digital Health

411

319

View full text Add to dashboard Cite

Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.

show abstract

Section: Challenges In Data Sharing and Securitymentioning

confidence: 99%

Artificial intelligence in COVID-19 drug repurposing

Zhou

Wang

Tang

et al. 2020

The Lancet Digital Health

411

319

View full text Add to dashboard Cite

show abstract

“…The first ethical frameworks for digital tools in the context of Covid-19 have been proposed (Mello and Wang 2020;Gasser et al 2020;Lucivero et al 2020;Kahn et al 2020;Morley et al 2020;Parker et al 2020), and the European Commission (2020) has drafted various recommendations and guidelines for digital contact tracing in the EU.…”

mentioning

confidence: 99%

Digital contact tracing and exposure notification: ethical guidance for trustworthy pandemic management

Ranisch

Nijsingh²,

Ballantyne

et al. 2020

Ethics Inf Technol

View full text Add to dashboard Cite

There is growing interest in contact tracing apps (CT apps) for pandemic management. It is crucial to consider ethical requirements before, while, and after implementing such apps. In this paper, we illustrate the complexity and multiplicity of the ethical considerations by presenting an ethical framework for a responsible design and implementation of CT apps. Using this framework as a starting point, we briefly highlight the interconnection of social and political contexts, available measures of pandemic management, and a multi-layer assessment of CT apps. We will discuss some trade-offs that arise from this perspective. We then suggest that public trust is of major importance for population uptake of contact tracing apps. Hasty, ill-prepared or badly communicated implementations of CT apps will likely undermine public trust, and as such, risk impeding general effectiveness.

show abstract

“…Both Facebook and Google both faced criticism for previous incidents in which consumer and health data was handled inappropriately (Newcomb 2018;Wakabayashi 2019). Regulation to prevent companies from improper use of consumer data and sunset provisions for the public health use of consumer data are some ways that privacy concerns could be addressed (Mello and Wang 2020).…”

Section: Orcidmentioning

confidence: 99%